<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl4" position="float"><object-id pub-id-type="doi">10.7554/eLife.22889.027</object-id><label>Table 4.</label><caption><p>Top 5 PD-1 residues contributing to electrostatic energy when binding to PD-L1 and pembrolizumab. Binding energies were calculated using the FastContact web server (<xref ref-type="bibr" rid="bib4">Champ and Camacho, 2007</xref>) and cocrystal structures of PD-1 bound to PD-L1 (<xref ref-type="bibr" rid="bib45">Zak et al., 2015</xref>) and pembrolizumab (<xref ref-type="bibr" rid="bib17">Horita et al., 2016</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22889.027">http://dx.doi.org/10.7554/eLife.22889.027</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top">PD-L1&#8211;bound</th><th colspan="2" valign="top">Pembrolizumab&#8211;bound</th></tr><tr><th valign="top">Residue</th><th valign="top">Energy (kcal/mol)</th><th valign="top">Residue</th><th valign="top">Energy (kcal/mol)</th></tr></thead><tbody><tr><td valign="top">Glu136<sup>*</sup></td><td valign="top">&#8722;11.531</td><td valign="top">Asp85<sup>&#8225;</sup></td><td valign="top">&#8722;8.367</td></tr><tr><td valign="top">Asp77</td><td valign="top">&#8722;5.073</td><td valign="top">Ser87</td><td valign="top">&#8722;3.629</td></tr><tr><td valign="top">Lys78<sup>&#8224;</sup> </td><td valign="top">&#8722;4.266</td><td valign="top">Asp77</td><td valign="top">&#8722;2.417</td></tr><tr><td valign="top">Gln75</td><td valign="top">&#8722;4.027</td><td valign="top">Tyr68</td><td valign="top">&#8722;2.156</td></tr><tr><td valign="top">Glu84</td><td valign="top">&#8722;3.119</td><td valign="top">Glu136</td><td valign="top">&#8722;2.096</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><sup>*</sup>The E136A mutation abolishes binding of PD-1 to PD-L1 and greatly reduces binding to PD-L2 (<xref ref-type="bibr" rid="bib22">L&#225;z&#225;r-Moln&#225;r et al., 2008</xref>).</p></fn><fn id="tblfn2"><p><sup>&#8224;</sup>The K78A mutation abolishes binding of PD-1 to PD-L1 and greatly reduces binding to PD-L2 (<xref ref-type="bibr" rid="bib22">L&#225;z&#225;r-Moln&#225;r et al., 2008</xref>).</p></fn><fn id="tblfn3"><p><sup>&#8225;</sup>The D85G mutation abolishes binding of PD-1 to pembrolizumab (<xref ref-type="bibr" rid="bib31">Na et al., 2017</xref>).</p></fn></table-wrap-foot></table-wrap>